Nucynta Related Published Studies
Well-designed clinical trials related to Nucynta (Tapentadol)
Tapentadol potentiates descending pain inhibition in chronic pain patients with
diabetic polyneuropathy. [2014]
Evaluation of blood pressure and heart rate in patients with hypertension who
received tapentadol extended release for chronic pain: a post hoc, pooled data
analysis. [2014]
Bowel function after tapentadol and oxycodone immediate release (IR) treatment in
patients with low back or osteoarthritis pain. [2013]
Effect of tapentadol extended release on productivity: results from an analysis
combining evidence from multiple sources. [2012]
Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting, constipation) of tapentadol compared with oxycodone hydrochloride. [2011.05]
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. [2011.01]
Post hoc analyses of data from a 90-day clinical trial evaluating the
tolerability and efficacy of tapentadol immediate release and oxycodone immediate
release for the relief of moderate to severe pain in elderly and nonelderly
patients. [2011]
Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: results of a randomized-withdrawal, placebo-controlled trial. [2010.12.02]
Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. [2010.09]
Evaluation of study discontinuations with tapentadol inmmediate release and oxycodone immediate release in patients with low back or osteoarthritis pain. [2010.05]
Dose conversion between tapentadol immediate and extended release for low back pain. [2010.01]
Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: results of two randomized, open-label, crossover, drug-drug interaction studies. [2010.01]
Efficacy and safety of Tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: a randomized, double-blind, placebo- and active-controlled phase III study. [2010]
Evaluation of study discontinuations with tapentadol inmmediate release and
oxycodone immediate release in patients with low back or osteoarthritis pain. [2010]
Efficacy and safety of tapentadol extended release for the management of chronic
low back pain: results of a prospective, randomized, double-blind, placebo- and
active-controlled Phase III study. [2010]
Dose conversion between tapentadol immediate and extended release for low back
pain. [2010]
A randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain. [2009.06]
Tolerability of tapentadol immediate release in patients with lower back pain or osteoarthritis of the hip or knee over 90 days: a randomized, double-blind study. [2009.05]
A randomized, double-blind, phase III study comparing multiple doses of tapentadol IR, oxycodone IR, and placebo for postoperative (bunionectomy) pain. [2009.03]
Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: a 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. [2009.02]
Single dose analgesic efficacy of tapentadol in postsurgical dental pain: the results of a randomized, double-blind, placebo-controlled study. [2008.12]
Other research related to Nucynta (Tapentadol)
Tapentadol-ER for the treatment of diabetic peripheral neuropathy. [2013]
Miotic and subject-rated effects of therapeutic doses of tapentadol, tramadol,
and hydromorphone in occasional opioid users. [2013]
Imputing at-work productivity loss using results of a randomized controlled trial
comparing tapentadol extended release and oxycodone controlled release for
osteoarthritis pain. [2012]
Bendamustine: a review of its use in the management of chronic lymphocytic
leukaemia, rituximab-refractory indolent non-Hodgkin's lymphoma and multiple
myeloma. [2012]
Systematic review of tapentadol in chronic severe pain. [2011.10]
Synergistic antihypersensitive effects of pregabalin and tapentadol in a rat model of neuropathic pain. [2011.09]
[Tapentadol is a new, strongly efficative analgeticum with dual effect mechanisms]. [2011.06.20]
Tapentadol in pain management: a mu-opioid receptor agonist and noradrenaline reuptake inhibitor. [2011.05.01]
Synergistic interaction between the two mechanisms of action of tapentadol in analgesia. [2011.04]
Mu-opioid and noradrenergic alpha(2)-adrenoceptor contributions to the effects of tapentadol on spinal electrophysiological measures of nociception in nerve-injured rats. [2011.01]
Comparable efficacy and superior gastrointestinal tolerability (nausea, vomiting,
constipation) of tapentadol compared with oxycodone hydrochloride. [2011]
Advances in perioperative pain management: use of medications with dual analgesic mechanisms, tramadol & tapentadol. [2010.12]
Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. [2010.10.01]
A thorough QT/QTc study of multiple doses of tapentadol immediate release in healthy subjects. [2010.10]
Analgesic update: tapentadol hydrochloride. [2010.10]
Tapentadol immediate release: a review of its use in the treatment of moderate to severe acute pain. [2010.09.10]
Cost-effectiveness analysis of tapentadol immediate release for the treatment of acute pain. [2010.09]
Differential contribution of opioid and noradrenergic mechanisms of tapentadol in rat models of nociceptive and neuropathic pain. [2010.09]
Efficacy and safety of tapentadol extended release for the management of chronic low back pain: results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. [2010.08]
Review of the effect of opioid-related side effects on the undertreatment of moderate to severe chronic non-cancer pain: tapentadol, a step toward a solution? [2010.07]
Long-term Safety and Tolerability of Tapentadol Extended Release for the Management of Chronic Low Back Pain or Osteoarthritis Pain. [2010.06.29]
Tapentadol immediate-release for acute pain. [2010.06]
Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. [2010.06]
Tapentadol: an initial analysis. [2010.05]
Tapentadol, but not morphine, selectively inhibits disease-related thermal hyperalgesia in a mouse model of diabetic neuropathic pain. [2010.02.12]
In vitro and in vivo characterization of tapentadol metabolites. [2010.01]
Tapentadol hydrochloride: a centrally acting oral analgesic. [2009.12]
Is tapentadol an advance on tramadol? [2009.11]
Tapentadol immediate release for the relief of moderate-to-severe acute pain. [2009.11]
Tapentadol hydrochloride: a next-generation, centrally acting analgesic with two mechanisms of action in a single molecule. [2009.07]
(-)-(1R,2R)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): a novel mu-opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. [2007.10]
Absorption, metabolism, and excretion of 14C-labeled tapentadol HCl in healthy male subjects. [2007.07]
Other possibly related research studies
Recent advances in postoperative pain management. [2010.03]
Gateways to clinical trials. [2009.10]
Gateways to clinical trials. [2009.07]
Opioid-induced constipation: challenges and therapeutic opportunities. [2011.05]
Validation of the Short-form McGill Pain Questionnaire-2 (SF-MPQ-2) in acute low
back pain. [2015]
Recent management advances in acute postoperative pain. [2014]
|